Cell therapy for relapsed follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (TC011) for people with follicular lymphoma that has come back or not responded to at least two prior treatments. The treatment uses your own immune cells, which are modified to fight the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have follicular lymphoma (Grade 1, 2, or 3a) that has come back or not responded to at least two prior treatments, including rituximab.
- You are able to get up and take care of yourself (ECOG score 0-2).
- You have at least one tumor that can be measured on a scan (≥1.5 cm).
- Your heart, lungs, liver, kidneys, and blood counts are working well enough for this treatment.
- You are willing to use effective birth control for 6 months after the infusion (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell that targets two markers (CD19 and CD22) on lymphoma cells. It is for patients whose lymphoma has come back or not responded after at least two prior treatments.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
This Phase 2 trial studies treatment options for follicular lymphoma that has returned or did not respond to prior therapy. It compares a standard chemotherapy approach against another study treatment to see which works better and is tolerable.
Hear when a new Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.